Executives from Corindus Vascular Robotics discuss the Company’s plans and strategies for improving stroke care in an interview with SmartTRAK at SNIS 2019

Although Corindus Vascular Robotics is known more for playing in the cardiovascular space, the Company is now leveraging its expertise in vascular robotics to expand into neurovascular applications and telerobotics with the goal of improving access to comprehensive stroke care. The Company’s CorPath GRX System received FDA clearance for percutaneous coronary interventions in 2016 and for peripheral vascular interventions in 2018. Since then, the CorPath GRX has received ...

Insera Therapeutics takes vacuum aspiration therapy to a new level with a disruptive digital design and cyclical aspiration for mechanical thrombectomy

Insera Therapeutics’ co-founders and brothers Vikram Janardhan and Vallabh Janardhan, MD saw an opportunity in the market for acute ischemic stroke and have developed a next generation, all digital vacuum aspiration system for mechanical thrombectomy designed to take suction aspiration to a new level. Unlike traditional analog electromechanical vacuum aspiration systems, which provide uniform, static aspiration, the Company’s CLEAR Aspiration System allows users to layer cyclical or pulsatile aspiration on top of uniform aspiration. By marrying a computer to a vacuum pump, Insera’s Clear Aspiration System can be finely controlled, and allows users to create their own cyclical wave patterns remotely using an iPad controller.

The Company recently received CE Mark for the Clear Aspiration System with a broad indication beyond stroke, and research to date suggests the technology provides better transmission suction to the tip, improves the first pass effect and decreases emboli in new territory.

To find out more about Insera Therapeutics, the technology and what’s next for the Company, SmartTRAK interviewed CEO Vikram Janardhan and Chief Medical Officer Vallabh Janardhan, MD, at the Society of Neurointerventional Surgery (SNIS) Annual Meeting in Miami Beach, FL held July 22-26, 2019.

Click on the following video to listen to SmartTRAK’s interview with Vikram and Vallabh Janardhan, MD, recorded live at SNIS 2019. To download a transcript of the interview, please click the button at the end of this post.

Cognition Medical discusses its next generation neurovascular technologies in an interview with SmartTRAK at SNIS 2019. 

Despite continued weakness and share shifts in Q219, the SCS market is poised to accelerate in H219 on new products/clinical data

In Q219, US and WW spinal cord stimulation (SCS) revenues were down for all the big players against tough YoY comps and ongoing weakness in the market as companies work through a gap in new product introductions, ongoing commercial execution issues and customer destocking. In the US, SCS revenues were down -6.3% vs Q218 according to the SmartTRAK Financial Dashboard. Although revenues were up sequentially per the usual seasonality in Q2, QoQ growth in Q219 was more anemic compared to the previous year. Between Q119-Q219, US SCS revenue was up just over ...

Among the many topics covered in the complete Q219 SCS Market Recap* are:

Intraoperative neuromonitoring could be a game changer in the field of SCS by elucidating the MOA for current and emerging SCS waveforms and stimulation patterns. But will it improve outcomes? To find out more, SmartTRAK interviewed Steven Falowski, MD at NANS 2019.

Historically, pain specialists have always placed spinal cord stimulators in awake patients for safety reasons and to confirm the therapy is adequately covering painful areas. However, Dr. Falowski says there’s been a paradigm shift where both pain physicians and surgeons alike are now using intraoperative neuromonitoring to place SCS systems for both percutaneous electrodes and paddle leads in asleep patients to more accurately localize the spinal cord midline and to improve intraoperative electrode placement and pain coverage... 

In an interview with SmartTRAK, Robert Levy, MD, president of the International Neuromodulation Society (INS), provides a preview of the research, emerging technologies, and trends in neuromodulation that will be at the INS 2019 14th World Congress to be held May 23-30, 2019 in Sydney, Australia. 

The meeting will highlight several important topics, including the use of neurostimulation to reduce opioid use, closed-loop neurostimulation, and advances in non-invasive brain stimulation, including for the treatment of post-traumatic stress disorder, depression, and for enhancing memory and learning.

In terms of research, Dr. Levy said Sam Eldabe, MD of the United Kingdom will provide a critical evaluation of clinical trials in neuromodulation. Researchers will also present the latest insight into mechanism of action, new data on neurostimulation for cardiac ischemia, as well as research on use of deep brain stimulation (DBS) for obesity, eating disorders and addiction. Researchers will also present important pivotal trial results, including: the Evoke Study (Saluda Medical), evaluating closed-loop spinal cord stimulation (SCS); the SURF study (Stimwave Technologies), comparing different wireless SCS frequencies and waveforms; and the ReActiv8 trial (Mainstay Medical), evaluating the use of a restorative neurostimulation system for nocioceptive chronic low back pain. 

On the technology front, the INS’s Innovation Day will highlight disruptive innovations in neuromodulation, and will feature panel discussions and presentations by researchers and major shareholders from early stage start-ups, middle-stage start-ups and well-established companies.

To find out more about the INS World Congress, click on the following video to listen to SmartTRAK’s interview with Dr. Levy recorded via phone from his office in Florida. A transcript of the interview is also provided below.

SmartTRAK highlights key takeaways from the recent North American Neuromodulation (NANS) 22nd annual meeting held in Las Vegas in January, including important company news, trials, technologies, and trends affecting the US market for spinal cord stimulation (SCS) and what's next in this market. This informative article also includes exclusive interviews with leading figures in Neuromodulation including Saluda Medical CEO John Parker, President Abbott Neuromodulation Keith Boetigger, Medtronic Senior VP and Pain Therapies President Marshall Stanton, and Medtronic Senior Global Product Manager for Pain Stimulation and Early Interventions Brian Ranck ...

The Spinal Cord Stimulation (SCS) market saw high-teens growth in FY18, but decelerated in Q418.

The US SCS Market saw another banner year in FY18, growing +17.4% YoY. Market growth was driven by new product launches, expanding indications and ongoing demand for non-narcotic alternatives that address chronic intractable pain and the opioid epidemic.

Anne Staylor, Managing Editor, Business Intelligence and Senior Director, Advanced Technologies will be representing BioMedGPS SmartTRAK at both conferences. Please Contact Usif you would like a meeting!

New Products, Continued Demand Provide SCS Market Tailwinds

SmartTRAK reports that with new products providing a strong tailwind in Q318, the SCS market saw another quarter of strong double-digit growth in both the US and WW, positioning the market for another record year. 

Among the many topics covered in the Q318 SCS Market Recap are: